Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Core One Labs Inc. (C:COOL)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 595 Burrard Street, Suite 3123
VANCOUVER BC V7X 1J1
Tel: N/A
Website: https://core1labs.com
IR: See website
Key People
Joel Shacker
Chief Executive Officer, Director
Geoffrey Balderson
Chief Financial Officer, Corporate Secretary, Director
 
Business Overview
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. The Company, through its wholly owned subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics.
Financial Overview
For the nine months ended 31 December 2023, Core One Labs Inc revenues decreased 48% to C$268K. Net loss decreased 49% to C$2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Share-based payments decrease of 92% to C$272K (expense), Wages and salaries decrease of 62% to C$233K (expense), Transaction expense decrease of 28% to C$411K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $10.36M as of Dec 31, 2023
Annual revenue (TTM): N/A
EBITDA (TTM): N/A
Net annual income (TTM): N/A
Free cash flow (TTM): -$1.55M as of Dec 31, 2023
Net Debt Last Fiscal Year: $0.10M as of Dec 31, 2023
Shares outstanding: 47,097,332 as of Jan 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization